Xperi vs. Doximity: A Comparative Study in Tech and Healthcare

The recent head-to-head financial reviews of Xperi Inc. (XPER) and Doximity Inc. (DOCS) highlight a stark contrast between a legacy-rich technology licensor and a high-growth digital platform. Xperi, which spun off its product business from its IP licensing arm (Adeia) in late 2022, is currently focused on scaling its independent media platform and automotive solutions. Doximity, conversely, has solidified its position as the 'LinkedIn for doctors,' leveraging a high-margin SaaS-like model that serves the pharmaceutical and healthcare recruitment sectors. This divergence in business models dictates their respective market valuations and investor appeal.

From a profitability standpoint, Doximity consistently outperforms Xperi. Doximity's business model is characterized by exceptionally high gross margins, often exceeding 80%, and robust net income margins that reflect the scalability of its digital network. The company’s primary revenue driver—pharmaceutical advertising—benefits from the high concentration of U.S. physicians on its platform, making it an indispensable tool for medical marketing. In contrast, Xperi’s financials are often weighed down by the heavy R&D and capital expenditures required to maintain its DTS and TiVo ecosystems. While Xperi is showing promise in the 'Connected Car' space with its DTS AutoStage platform, it remains in a transitional phase where revenue growth must eventually outpace the costs of platform deployment.

“

Doximity's business model is characterized by exceptionally high gross margins, often exceeding 80%, and robust net income margins that reflect the scalability of its digital network.

Institutional ownership remains a critical metric for both entities, signaling long-term confidence from major asset managers. Both companies boast high institutional backing, with firms like Vanguard Group and BlackRock maintaining significant positions. However, the sentiment among these institutions differs. Investors in Doximity are largely betting on the continued digitalization of healthcare workflows and the expansion of telehealth services. Investors in Xperi are more focused on the 'sum-of-the-parts' valuation, hoping that the company’s intellectual property in audio, imaging, and streaming will eventually lead to a lucrative buyout or a significant expansion in licensing royalties from smart TV manufacturers and automakers.